2,6-difluoro-N-(quinolin-8-yl)benzenesulfonamide | 1177862-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,6-difluoro-N-(quinolin-8-yl)benzenesulfonamide
• 英文别名: 2,6-Difluoro-N-quinolin-8-yl-benzenesulfonamide；2,6-difluoro-N-quinolin-8-ylbenzenesulfonamide
• CAS: 1177862-02-0
• 化学式: C₁₅H₁₀F₂N₂O₂S
• 分子量: 320.319
• InChiKey: ZWOCMXJGOLXDPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  8-氨基喹啉 、 2,6-二氟苯磺酰氯 在 吡啶 作用下， 反应 0.05h， 以83%的产率得到2,6-difluoro-N-(quinolin-8-yl)benzenesulfonamide
  参考文献：
  名称：

  从传感器到消音器：作为锌蛋白酶抑制剂的喹啉和苯并咪唑磺酰胺

  摘要：

  源自小分子锌 (II) 离子传感器领域的广泛工作，已经制备了喹啉和苯并咪唑磺酰胺的螯合片段库，并针对几种不同的锌 (II) 依赖性基质金属蛋白酶 (MMP) 进行了筛选。基于螯合基团的性质，这些片段显示出对这些金属酶的显着抑制和对不同 MMP 的偏好。研究结果表明，聚焦螯合剂文库是发现用于金属蛋白抑制的先导片段的有力策略。

  DOI：

  10.1021/ja101088j

文献信息

• Novel Sulfonaminoquinoline Hepcidin Antagonists
  申请人：Buhr Wilm

  公开号：US20120214803A1

  公开（公告）日：2012-08-23

  The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

  本发明涉及新型肝铁蛋白拮抗剂，包括它们的药物组合物以及将其用作药物治疗铁代谢紊乱，特别是铁缺乏病和贫血等疾病，特别是与慢性炎症性疾病相关的贫血。
• Sulfonaminoquinoline hepcidin antagonists
  申请人：Vifor (International) AG

  公开号：US09102688B2

  公开（公告）日：2015-08-11

  The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

  本发明涉及新型的赫普西丁拮抗剂，包括它们的药物组合物和将其作为药物用于治疗铁代谢紊乱的用途，特别是铁缺乏症和贫血，特别是与慢性炎症性疾病相关的贫血。
• NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS
  申请人：Vifor (International) AG

  公开号：EP2675526A1

  公开（公告）日：2013-12-25
• COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS
  申请人：Pellecchia Maurizio

  公开号：US20100041653A1

  公开（公告）日：2010-02-18

  The present disclosure provides compounds having the general structure A or pharmaceutically acceptable salts thereof: R—X  (A) wherein R is an alkyl or aryl moiety comprising heterocyclic structures; and X is a metal-chelatin group selected from: This disclosure further provides a focused library of compounds for use in the discovery and design of metallo-enzyme inhibitors. This fragment-based approach provides an assembly of a library of low molecular weight compounds (MW<300 Da) containing a variety of potential metal-chelating groups. The identification of the inhibitory scaffolds among these compounds provides the initial hit fragments that may be optimized for affinity against a particular target using common medicinal chemistry, structure-based or NMR-based approaches.
• US9102688B2
  申请人：——

  公开号：US9102688B2

  公开（公告）日：2015-08-11